Bypassing glycosylation: Engineering aglycosylated full-length IgG antibodies for human therapy

Current Opinion in Biotechnology

Volumn 22, Issue 6, 2011, Pages 858-867

  Jung, Sang Taek ^a   Kang, Tae Hyun ^a   Kelton, William ^a   Georgiou, George ^a,b  

^a The University of Texas at Austin   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOPROCESS DEVELOPMENT; BIOPROCESSING; CLINICAL EVALUATION; GLYCOSYLATED; IMMUNOGENICITY; IN-VIVO; LOWER EUKARYOTES; PROTEIN THERAPEUTICS; RUNNING TIME; THERAPEUTIC ANTIBODIES;

BIOTECHNOLOGY;

ANTIBODIES;

ANTIBODY OA 5D5; ANTIBODY TRX1; ANTIBODY TRX518; BMS 945429; CD3 ANTIGEN; CD4 ANTIGEN; FC RECEPTOR; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 120 ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 6; N ACETYLGLUCOSAMINE; OTELIXIZUMAB; RITUXIMAB; SCATTER FACTOR; SIALIC ACID; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTIBODY AFFINITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY ENGINEERING; ANTIGEN BINDING; ANTIINFLAMMATORY ACTIVITY; BINDING AFFINITY; COMPLEMENT DEPENDENT CYTOTOXICITY; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DEGLYCOSYLATION; DRUG HALF LIFE; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; RESIDUE ANALYSIS; REVIEW; SIGNAL TRANSDUCTION; THERMOSTABILITY; VIRUS NEUTRALIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL; BACTERIA; BIOTECHNOLOGY; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN G; IMMUNOTHERAPY;

EUKARYOTA;

EID: 80052622662     PISSN: 09581669     EISSN: 18790429     Source Type: Journal    
DOI: 10.1016/j.copbio.2011.03.002     Document Type: Review

References (71)

1. Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 2009, 8:226-234.
2. Hamilton S.R., Bobrowicz P., Bobrowicz B., Davidson R.C., Li H., Mitchell T., Nett J.H., Rausch S., Stadheim T.A., Wischnewski H., et al. Production of complex human glycoproteins in yeast. Science 2003, 301:1244-1246.
3. Cox K.M., Sterling J.D., Regan J.T., Gasdaska J.R., Frantz K.K., Peele C.G., Black A., Passmore D., Moldovan-Loomis C., Srinivasan M., et al. Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor. Nat Biotechnol 2006, 24:1591-1597.
4. Strasser R., Stadlmann J., Schähs M., Stiegler G., Quendler H., Mach L., Glössl J., Weterings K., Pabst M., Steinkellner H. Generation of glyco engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human like N glycan structure. Plant Biotechnol J 2008, 6:392-402.
5. Schuster M., Jost W., Mudde G., Wiederkum S., Schwager C., Janzek E., Altmann F., Stadlmann J., Stemmer C., Gorr G. In vivo glyco-engineered antibody with improved lytic potential produced by an innovative non-mammalian expression system. Biotechnol J 2007, 2:700-708.
6. Li H., Sethuraman N., Stadheim T., Zha D., Prinz B., Ballew N., Bobrowicz P., Choi B., Cook W., Cukan M. Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nat Biotechnol 2006, 24:210-215.
7. Adair J. Engineering antibodies for therapy. Immunol Rev 1992, 130:5-40.
8. Tran M., Zhou B., Pettersson P., Gonzalez M., Mayfield S. Synthesis and assembly of a full length human monoclonal antibody in algal chloroplasts. Biotechnol Bioeng 2009, 104:663-673.
9. Keymeulen B., Vandemeulebroucke E., Ziegler A., Mathieu C., Kaufman L., Hale G., Gorus F., Goldman M., Walter M., Candon S. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. New Engl J Med 2005, 352:2598-2608.
10. Friend P., Hale G., Chatenoud L., Rebello P., Bradley J., Thiru S., Phillips J., Waldmann H. Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection. Transplantation 1999, 68:1632-1637.
11. Hale G., Rebello P., Al Bakir I., Bolam E., Wiczling P., Jusko W.J., Vandemeulebroucke E., Keymeulen B., Mathieu C., Ziegler A.G., et al. Pharmacokinetics and antibody responses to the CD3 antibody otelixizumab used in the treatment of type 1 diabetes. J Clin Pharmacol 2010, 50:1238-1248.
12. Wiczling P., Rosenzweig M., Vaickus L., Jusko W.J. Pharmacokinetics and pharmacodynamics of a chimeric/humanized anti-CD3 monoclonal antibody, otelixizumab (TRX4), in subjects with psoriasis and with type 1 diabetes mellitus. J Clin Pharmacol 2010, 50:494-506.
13. Keymeulen B., Walter M., Mathieu C., Kaufman L., Gorus F., Hilbrands R., Vandemeulebroucke E., Van de Velde U., Crenier L., De Block C. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 2010, 53:614-623.
14. Schaer D.A., Cohen A.D., Wolchok J.D. Anti-GITR antibodies - potential clinical applications for tumor immunotherapy. Curr Opin Investig Drugs 2010, 11:1378-1386.
15. Ng C., Stefanich E., Anand B., Fielder P., Vaickus L. Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers. Pharm Res 2006, 23:95-103.
16. Clarke S., Smith J., Gebbie C., Sweeney C., Olszewski N. A phase I, pharmacokinetic (PK), and preliminary efficacy assessment of ALD518, a humanized anti-IL-6 antibody, in patients with advanced cancer. Am Soc Clin Oncol 2009, 3025.
17. Eder J.P., Vande Woude G.F., Boerner S.A., LoRusso P.M. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 2009, 15:2207-2214.
18. Yap T.A., de Bono J.S. Targeting the HGF/c-Met axis: state of play. Mol Cancer Ther 2010, 9:1077-1079.
19. Georgiou G., Segatori L. Preparative expression of secreted proteins in bacteria: status report and future prospects. Curr Opin Biotechnol 2005, 16:538-545.
20. Mattu T., Pleass R., Willis A., Kilian M., Wormald M., Lellouch A., Rudd P., Woof J., Dwek R. The glycosylation and structure of human serum IgA1, Fab, and Fc regions and the role of N-glycosylation on Fcα receptor interactions. J Biol Chem 1998, 273:2260-2272.
21. Liu H., Bulseco G.-G., Sun J. Effect of posttranslational modifications on the thermal stability of a recombinant monoclonal antibody. Immunol Lett 2006, 106:144-153.
22. Raju T. Impact of Fc glycosylation on monoclonal antibody effector functions and degradation by proteases. Current Trends in Monoclonal Antibody Development and Manufacturing 2010, 249-269. Springer, New York. S.J. Shire, W. Gombotz, K. Bechtold-Peters, J. Andya (Eds.).
23. Kayser V., Chennamsetty N., Voynov V., Forrer K., Helk B., Trout B.L. Glycosylation influences on the aggregation propensity of therapeutic monoclonal antibodies. Biotechnol J 2011, 6:38-44.
24. Tao M., Morrison S. Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J Immunol 1989, 143:2595-2601.
25. Raju T., Scallon B. Glycosylation in the Fc domain of IgG increases resistance to proteolytic cleavage by papain. Biochem Biophy Res Commun 2006, 341:797-803.
26. Raju T., Scallon B. Fc glycans terminated with N acetylglucosamine residues increase antibody resistance to papain. Biotechnol Prog 2007, 23:964-971.
27. Mimura Y., Church S., Ghirlando R., Ashton P., Dong S., Goodall M., Lund J., Jefferis R. The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms. Mol Immunol 2000, 37:697-706.
28. Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 2009, 8:226-234.
29. Jefferis R. Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action. Trends Pharmacol Sci 2009, 30:356-362.
30. Bruhns P., Iannascoli B., England P., Mancardi D.A., Fernandez N., Jorieux S., Daëron M. Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses. Blood 2009, 113:3716-3725.
31. Krapp S., Mimura Y., Jefferis R., Huber R., Sondermann P. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J Mol Biol 2003, 325:979-989.
32. Naso M.F., Tam S.H., Scallon B.J., Raju T.S. Engineering host cell lines to reduce terminal sialylation of secreted antibodies. MAbs 2010, 2:519-527.
33. Kubota T., Niwa R., Satoh M., Akinaga S., Shitara K., Hanai N. Engineered therapeutic antibodies with improved effector functions. Cancer Sci 2009, 100:1566-1572.
34. 1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity. J Biol Chem 2002, 277:26733-26740.
35. Yamane-Ohnuki N., Satoh M. Production of therapeutic antibodies with controlled fucosylation. MAbs 2009, 1:230-236.
36. Nimmerjahn F., Ravetch J.V. Fcγ receptors as regulators of immune responses. Nat Rev Immunol 2008, 8:34-47.
37. Malphettes L., Freyvert Y., Chang J., Liu P.-Q., Chan E., Miller J.C., Zhou Z., Nguyen T., Tsai C., Snowden A.W., et al. Highly efficient deletion of FUT8 in CHO cell lines using zinc-finger nucleases yields cells that produce completely nonfucosylated antibodies. Biotechnol Bioeng 2010, 106:774-783.
38. Natsume A., Shimizu-Yokoyama Y., Satoh M., Shitara K., Niwa R. Engineered anti-CD20 antibodies with enhanced complement-activating capacity mediate potent anti-lymphoma activity. Cancer Sci 2009, 100:2411-2418.
39. Davies J., Jiang L., Pan L.-Z., LaBarre M.J., Anderson D., Reff M. Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FcγRIII. Biotechnol Bioeng 2001, 74:288-294.
40. Umaña P., Jean-Mairet J., Moudry R., Amstutz H., Bailey J.E. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol 1999, 17:176-180.
41. Mössner E., Brunker P., Moser S., Puntener U., Schmidt C., Herter S., Grau R., Gerdes C., Nopora A., van Puijenbroek E., et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010, 115:4393-4402.
42. Anthony R., Ravetch J. A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. J Clin Immunol 2010, 30:9-14.
43. Anthony R.M., Nimmerjahn F., Ashline D.J., Reinhold V.N., Paulson J.C., Ravetch J.V. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 2008, 320:373-376.
44. Strasser R., Castilho A., Stadlmann J., Kunert R., Quendler H., Gattinger P., Jez J., Rademacher T., Altmann F., Mach L., et al. Improved virus neutralization by plant-produced anti-HIV antibodies with a homogeneous beta1,4-galactosylated N-glycan profile. J Biol Chem 2009, 284:20479-20485.
45. Forthal D.N., Gach J.S., Landucci G., Jez J., Strasser R., Kunert R., Steinkellner H. Fc-glycosylation influences Fcγ receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12. J Immunol 2010, 185:6876-6882.
46. Jung S.T., Reddy S.T., Kang T.H., Borrok M.J., Sandlie I., Tucker P.W., Georgiou G. Aglycosylated IgG variants expressed in bacteria that selectively bind FcγRI potentiate tumor cell killing by monocyte-dendritic cells. Proc Natl Acad Sci USA 2010, 107:604-609.
47. Lund J., Takahashi N., Pound J.D., Goodall M., Jefferis R. Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fcγ receptor I and influence the synthesis of its oligosaccharide chains. J Immunol 1996, 157:4963-4969.
48. Feige M.J., Nath S., Catharino S.R., Weinfurtner D., Steinbacher S., Buchner J. Structure of the murine unglycosylated IgG1 Fc fragment. J Mol Biol 2009, 391:599-608.
49. Houde D., Arndt J., Domeier W., Berkowitz S., Engen J.R. Characterization of IgG1 conformation and conformational dynamics by hydrogen/deuterium exchange mass spectrometry. Anal Chem 2009, 81:2644-2651.
50. Barb A.W., Prestegard J.H. NMR analysis demonstrates immunoglobulin G N-glycans are accessible and dynamic. Nat Chem Biol 2011, 7:147-153.
51. Lazar G.A., Dang W., Karki S., Vafa O., Peng J.S., Hyun L., Chan C., Chung H.S., Eivazi A., Yoder S.C., et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA 2006, 103:4005-4010.
52. Richards J.O., Karki S., Lazar G.A., Chen H., Dang W., Desjarlais J.R. Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells. Mol Cancer Ther 2008, 7:2517-2527.
53. Moore G.L., Chen H., Karki S., Lazar G.A. Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. MAbs 2010, 2:181-189.
54. Lazar GA, Chirino AJ, Dang W, Desjarlais JR, Doberstein SK, Hayes RJ, Karki SB, Vafa O: Optimized Fc variants and methods for their generation. US Patent 2009:20090092599.
55. 1 variants productively engage activating Fc receptors. Proc Natl Acad Sci USA 2008, 105:20167-20172.
56. Boruchov A.M., Heller G., Veri M.-C., Bonvini E., Ravetch J.V., Young J.W. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J Clin Invest 2005, 115:2914-2923.
57. Dhodapkar K., Kaufman J., Ehlers M., Banerjee D., Bonvini E., Koenig S., Steinman R., Ravetch J., Dhodapkar M. Selective blockade of inhibitory Fcγ receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. Proc Natl Acad Sci USA 2005, 102:2910-2915.
58. Dhodapkar K., Banerjee D., Connolly J., Kukreja A., Matayeva E., Veri M., Ravetch J., Steinman R., Dhodapkar M. Selective blockade of the inhibitory Fc receptor (FcγRIIB) in human dendritic cells and monocytes induces a type I interferon response program. J Exp Med 2007, 204:1359-1369.
59. Smith K.G.C., Clatworthy M.R. FcγRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat Rev Immunol 2010, 10:328-343.
60. Brooks D.G., Qiu W.Q., Luster A.D., Ravetch J.V. Structure and expression of human IgG FcRII(CD32). Functional heterogeneity is encoded by the alternatively spliced products of multiple genes. J Exp Med 1989, 170:1369-1385.
61. Simmons L.C., Reilly D., Klimowski L., Raju T.S., Meng G., Sims P., Hong K., Shields R.L., Damico L.A., Rancatore P., et al. Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies. J Immunol Methods 2002, 263:133-147.
62. Zalevsky J., Chamberlain A.K., Horton H.M., Karki S., Leung I.W., Sproule T.J., Lazar G.A., Roopenian D.C., Desjarlais J.R. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol 2010, 28:157-159.
63. 1 variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates. Drug Metab Dispos 2007, 35:86-94.
64. Dall'Acqua W.F., Kiener P.A., Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 2006, 281:23514-23524.
65. Cabilly S., Riggs A.D., Pande H., Shively J.E., Holmes W.E., Rey M., Perry L.J., Wetzel R., Heyneker H.L. Generation of antibody activity from immunoglobulin polypeptide chains produced in Escherichia coli. Proc Natl Acad Sci USA 1984, 81:3273-3277.
66. Reilly D.E., Yansura D.G. Production of monoclonal antibodies in E. coli. Current Trends in Monoclonal Antibody Development and Manufacturing 2010, 295-308. Springer, New York. S.J. Shire, W. Gombotz, K. Bechtold-Peters, J. Andya (Eds.).
67. Chan C.E., Lim A.P., Chan A.H., MacAry P.A., Hanson B.J. Optimized expression of full-length IgG1 antibody in a common E. coli strain. PLoS ONE 2010, 5:e10261.
68. Mazor Y., Van Blarcom T., Mabry R., Iverson B.L., Georgiou G. Isolation of engineered, full-length antibodies from libraries expressed in Escherichia coli. Nat Biotechnol 2007, 25:563-565.
69. Mazor Y., Van Blarcom T., Carroll S., Georgiou G. Selection of full-length IgGs by tandem display on filamentous phage particles and Escherichia coli fluorescence-activated cell sorting screening. FEBS J 2010, 277:2291-2303.
70. Makino T., Skretas G., Kang T.H., Georgiou G. Comprehensive engineering of Escherichia coli for enhanced expression of IgG antibodies. Metab Eng 2011, 13:241-251.
71. Hakim R., Benhar I. Inclonals: IgGs and IgG-enzyme fusion proteins produced in an E. coli expression-refolding system. MAbs 2009, 1:281-287.